Anxiety and its disorders: Implications for pharmacotherapy
RIS ID
106477
Abstract
Otto, McHugh, and Kantak (2010) have crafted a model to account for the observation that pharmacologic treatments do not reliably add to the effectiveness of cognitive-behavioral therapy (CBT) for anxiety disorders. In this commentary, we discuss the nature of anxiety and its disorders and review three approaches to the pharmacotherapy of these psychological disorders. When the implications of these approaches are considered, the use of N-methyl-d-aspartate agonists, in theory, holds the greatest promise for a pharmacological treatment to complement CBT for anxiety disorders.
Publication Details
Abramowitz, J. S. & Deacon, B. (2010). Anxiety and its disorders: Implications for pharmacotherapy. Clinical Psychology: science and practice, 17 (2), 104-106.